Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Liquid Ready-to-use Tumour Marker Control available now from Randox

Published: Thursday, November 22, 2012
Last Updated: Thursday, November 22, 2012
Bookmark and Share
The new Randox Acusera multi-analyte Liquid Tumour Marker Control covers a total of 15 commonly tested and esoteric cancer antigens and tumour markers.

The inclusion of assayed, instrument specific target values enables laboratories to effectively monitor both accuracy and precision.

The Liquid Tumour Marker Control includes AFP (Alpha-fetoprotein), Beta-2- Microglobulin, CA15-3,3xVials01---New-Randox-TM-c.gif CA19-9, CA27-29, CA72-4, CA125, CEA (Carcinoembryonic Antigen), Cyfra 21-1, Ferritin, hCG (Human Chorionic Gonadotropin), NSE (Neuron-specific Enolase), PSA Free (Prostate Specific Antigen Free), PSA Total (Prostate Specific Antigen Total) and Thyroglobulin.

The liquid ready-to-use format is highly convenient for laboratory staff to use requiring no preparation. Furthermore the material can be easily shipped and stored at +2-8oC.  Liquid stable controls not only eliminate the need for reconstitution but reduce the amount of human handling necessary. The user friendly 6 x 3ml pack size and open vial stability of 30 days at +2-8oC for all analytes listed significantly helps to minimise waste and keep running costs low.

Like all Randox immunoassay controls the serum is 100% human in origin providing a matrix similar to the patient sample but also reducing antibody cross reactivity and the possibility of control values shifting when reagent batch is changed. Three distinct levels of control are available with all analytes including PSA present at desirable levels.  Clinically relevant PSA levels ensure the ratio of free to bound PSA is typical of that found in cancer patients.

As a true third party control laboratories can use the Acusera liquid tumour marker control to independently assess analytical performance.  Fully assayed, instrument specific target values and ranges are provided for many common clinical chemistry and immunoassay systems.

For optimum performance and advanced analytical capabilities use in combination with Acusera 24.7 Live Online, an inter-laboratory data management programme designed to monitor analytical performance, interpret QC results and improve the effectiveness of quality control. With Acusera 24.7 users benefit from online access anytime, peer group data generated from thousands of laboratories every 24 hours, fully interactive charts and reports and automatic import of QC data direct from your LIMs or instrument via Acusera 24.7 Connect.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!